Concr

Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can make advanced predictions about biomarkers by leveraging Concr’s unique technology, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Cambridge Angels, Deep Science Ventures and SyndicateRoom